1. STEPping stones to effective obesity management - Exploring the role of Semaglutide 2.4 mg (002).pptx

OBESITY MANAGEMENT

1. Driving change to defeat chronic diseases. Our purpose Driving a sustainable business and living up to our values as a company compels us to look at issues holistically and proactively address the underlying drivers behind the rise in serious chronic diseases .

2. The core values of the company began with our founders and are as strong today Our heritage

3. The Beginning Insulin: the beginning of our journey to save and improve lives

4. 2003 2013 2010 2019 2015 2022 1994 NNIPL established NOVO NORDISK INDIA FOOTPRINT IN DIABETES CARE

5. Range of Insulin

6. Agenda of the day T opic Speak er Introduction and context setting Novo Nordisk STEPping stones to effective obesity management: Exploring the role of Semaglutide 2.4 mg Speaker 01 Mending broken hearts with Semaglutide 2.4 mg in obesity management Speaker 02 Practical know-hows of using Semaglutide 2.4 mg All Faculty Conclusion and closing remarks Novo Nordisk Discussion over lunch/dinner

7. *The information, advocacy, suggestions and/or updates provided during the scheduled webinar is not intended or implied to be directed towards HCPs practicing outside the geographical territory of India We request you to note the few below mentioned important points :   Lecture Material : Kindly provide correct and full references to relevant publications on any use of third party’s work including, but not limited to, reproductions, quotes, adaptations or translations if any, used for the lecture. Off-label Communication/Promotion: During your lecture, we request you to kindly refrain from any off-label communication and/or promotion relating to any Novo Nordisk products or otherwise. Financial Disclosure : As part of your lecture, as well as whenever you write or speak in public about a matter that is relating to this lecture or otherwise about Novo Nordisk, please disclose that you have been supported by Novo Nordisk, if so is the case. The information, advocacy, suggestions and/or updates to be provided during the scheduled meeting is not intended or implied to be directed towards HCPs practicing outside the geographical territory of India. For the purpose of the event, we may use your portrait image in the event related publications – e.g. agenda, invitations etc. Please do let us know if you do not consent for the same.

8. Financial Disclosure The speaker has been commercially supported by Novo Nordisk for this medical educational meeting, in return for providing a service, and has no actual or potential conflict of interest in relation to this presentation.

9. 9 Tiwari DD, Thorat VM, Pakale PV. Newer Insulin Preparations and Insulin Analogs. Cureus. 2024 Nov 27;16(11). Continuous Innovation in Insulins Animal Insulins Human Insulins Human Insulins Insulin Analogues to improve A Lot Has Changed Over Time with Insulins

10. Key Limitations of Conventional Insulins More dose requirement Rigid dosing schedule Less predictability / high variability Slow onset Tiwari DD, Thorat VM, Pakale PV. Newer Insulin Preparations and Insulin Analogs. Cureus. 2024 Nov 27;16(11). High risk of hypoglycemia No flexibility Pronounced peak Delayed action Variable absorption

11. Advantages*: OD or BD dosing with the largest meal(s) of the day Better control of FPG No shoulder effect Lower risk of hypoglycemia Lower insulin dose requirement 11 *vs BIAsp 30; Garber et al. Diabetes Obes Metab 2006;8:58–66; Davidson et al. Clin Ther 2009;31:1641–51; Fulcher et al. Diabetes Care 2014;37:2084–90; 2. Kaneko et al. Diabetes Res Clin Pract 2015;107:139–47 Biphasic human insulin Limitations : Lack of meal-time dosing flexibility Shoulder effect Opportunity for better FPG and PPG control Lack of longer duration of action of basal component Biphasic analogue insulin Limitations : Opportunity for better FPG control Shoulder effect Lack of meal-time dosing flexibility Ryzodeg TM Moving Towards PwD -centric Solutions with New Generation Co-formulation Insulin

12. Co-formulation is different from premix insulins Atkin Ther Adv Chronic Dis 2015;6:375–88; 2. Kruszynska et al. Diabetologia 1987;30:16–21 Co-formulation Ultra-long acting Degludec (70%) Short acting aspart (30%) Ryzodeg™ FPG + PPG management

13. Ryzodeg TM at a Glance 1.Onishi Y et al. Diabetes Obes Metab 2013;15:826–32, 2. Shigiyama F et al. Diabetes Therapy. 2021 Sep;12:2405-21. 3. Ryzodeg TM CDSCO approved package insert version dated 14 October 2021, 4. Makkar BM.Int J Diabetes Dev Ctries  42 (Suppl 1), 1–143 (2022)., 5. Abstract presentation at ESICON 2022 presented by M.P.Baruah Effective HbA1c Reduction Effective FPG & PPG Reduction Lower Risk of Nocturnal Hypoglycemia Improved Quality of Life Mealtime Flexibility of Dosing More People Achieving Glycemic Targets Cost-effective Treatment Option RSSDI Recommended Insulin Initiation Option

14. Unmet needs of First-generation Basal Analogues* *Glargine U100, Detemir Cheng. Diabetes Ther (2020) 11:2555–2593

15. Tresiba ® Onset & duration of action Onset of action Peak of action Duration of action NPH 2-4 hours 4-12 hours 12-24 hours GlargineU100 2-4 hours 8-12 hours 22-24 hours Tresiba® 0.5-1.5 hours Minimal peak >42 hours Donner T, Sarkar S. Insulin–pharmacology, therapeutic regimens, and principles of intensive insulin therapy; Danne T, Philip M, Buckingham BA, Jarosz- Chobot P, Saboo B, Urakami T et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135. Tresiba® has a faster onset of action & prolonged duration of action with a minimal peak

16. Faster onset and longer duration of action 1 Better Dose-time Flexibility 5 Lower within day and day-to-day variability 2 Better efficacy 3 Proven safety profile in RCTs and RWEs 4 Action Variability Efficacy Safety Convenience Time to upgrade Tresiba® vs Glargine U100 1. Donner T, Sarkar S. Insulin–pharmacology, therapeutic regimens, and principles of intensive insulin therapy; Danne T, Philip M, Buckingham BA, Jarosz- Chobot P, Saboo B, Urakami T et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135., 2. Heise et al. Expert Opin Drug Metab Toxicol 2015;11:1193–201, 3. Kesavadev J, Murthy LS, Chaudhury T, et al. One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India-TRUST (Tresiba real-world use study). Metabol Open. 2022;14:100184. Published 2022 Apr 18. doi:10.1016/j.metop.2022.100184 ,, 4. Ratner et al. Diabetes Obes Metab 2013; 15:175-84, Seigmund et al. Presented at ADA 2017, 9-13 June 2017, San Diego, CA, USA, 5. Mathieu C et al. Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26- Week Randomized, Treat-to-Target Trial With a 26-Week Extension. J Clin Endocrinol Metab . 2013 Mar; 98(3): 1154–1162 Diabetes Technol Ther. 2016 Apr 1; 18(4): 252–257

17. Mimicking Physiology Better with New Generation Bolus / Mealtime Insulins Heinemann et al. Exp Clin Endocrinol Diabetes 1997;105:140–4; Home et al. Diabet Med 2000;17 Heise et al. Clin Pharmacokinet 2017;56:551–9; Russell-Jones et al. Diabetes Care 2017;40:943-950, Actrapid ® CDSCO approved package insert version dated 11 March 2022, Novo Nordisk. Insulin aspart ( NovoRapid ®) Summary of Product Characteristics. Accessed June 2017., iasp pack insert as per (8-0911-26-001-3 and 8-0910-26-001-30 DATED (23 Dec 2020) https://www.ema.europa.eu/en/documents/product-information/fiasp-epar-product-information_en.pdf Regular human insulin Insulin aspart Fiasp ® Insulin type Short acting insulin Rapid acting analog Ultra fast acting analog Early glucose lowering effect - Greater early-glucose lowering effect vs RHI Greater early-glucose lowering effect vs aspart Post meal dosing No Can be administered soon after a meal when necessary Can be administered upto 20 mins after the start of the meal Mimicking physiology

18. Convenience: Meal-time Dosing Flexibility Post-meal Dosing Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes 2018;42( Suppl 1):S80e7.; FiAsp PI Start of meal 2mins before 20 mins after Insulin Faster aspart

19. New Generation Insulins - Ryzodeg TM , Tresiba ® and Fiasp ® are Designed for Greater Efficacy, Improved Safety, and Better Convenience (vs Conventional Insulins) Tiwari DD, Thorat VM, Pakale DPV. Newer Insulin Preparations and Insulin Analogs . Cureus . 2024 Nov 27;16(11 )

20. Just like T2D, Obesity is Another Serious Chronic Condition that Needs Treatment 1. Anjana RM et al.). Lancet Diabetes Endocrinol 2023.Published Online June 7, 2023https://doi.org/10.1016/S2213-8587(23)00119-5 2. Rehman T et al.Indian J Community Med. 2020;45(3):315-319. 3. Venkatrao M et al.Annals of Neurosciences. 2020;27(3-4):153-161.. 4. Central Obesity: measured as waist circumference, waist–hip ratio, visceral fat mass, and posterior subcutaneous abdominal fat. ~ 67% people with T2DM in India have obesity 1,2 7 × INCREASED † RISK OF ALL-CAUSE MORTALITY (aged 51–61 years) 1 †Compared with people without diabetes of normal weight; p<0.05 101 million adults have T2DM 1 4 in 10 adults have Obesity 3 BMI (kg/m 2 ) 20.4% Overweight 67.3% Obesity 1,2

21. Panel discussion 22 STEPping stones to effective obesity management: Exploring the role of Semaglutide 2.4 mg

22. We request you to note the few below mentioned important points :   Lecture Material : Kindly provide correct and full references to relevant publications on any use of third party’s work including, but not limited to, reproductions, quotes, adaptations or translations if any, used for the lecture. Off-label Communication/Promotion: During your lecture, we request you to kindly refrain from any off-label communication and/or promotion relating to any Novo Nordisk products or otherwise. Financial Disclosure : As part of your lecture, as well as whenever you write or speak in public about a matter that is relating to this lecture or otherwise about Novo Nordisk, please disclose that you have been supported by Novo Nordisk, if so is the case. The information, advocacy, suggestions and/or updates to be provided during the scheduled meeting is not intended or implied to be directed towards HCPs practicing outside the geographical territory of India. For the purpose of the event, we may use your portrait image in the event related publications – e.g. agenda, invitations etc. Please do let us know if you do not consent for the same.

23. Financial Disclosure The speaker has been commercially supported by Novo Nordisk for this medical educational meeting, in return for providing a service, and has no actual or potential conflict of interest in relation to this presentation.

24. Is obesity only a result of voluntary excessive energy intake and decreased energy expenditure? 1. Hall KD, et al. Am J Clin Nutr . 2022;115:1243–54; 2. Herrera BM, Lindgren CM. Curr Diab Rep. 2010;10:498–505; 3. Sominsky L, Spencer SJ. Front Psychol. 2014;5:434; 4. Luppino FS et al. Arch Gen Psychiatry. 2010;67:220 – 9; 5. Loring & Robertson. 2014. The Regional Office for Europe of the World Health Organization, pp.4 ; 6. Janssen LK & Juk JL. Canadian Adult Obesity. Available from https://obesitycanada.ca/guidelines/epidemiology. Accessed July 2022; 7. Lau D et al. Canadian Adult Obesity Clinical Practice Guidelines: The Science of Obesity. Available from https://obesitycanada.ca/guidelines/science. Accessed November 2022. Many paths can lead to obesity Obesity is caused by a complex interplay of several factors. It is a chronic disease in which abnormal or excess adiposity impairs health, increases the risk of long-term medical complications and reduces life span. Biological The brain controls eating behavior and appetite Psychological Stress and psychological distress impact appetite Genetic Around 40-70% of our weight is dependent on our genetic make-up Social Health, social and economic inequalities Environmental Unhealthy eating patterns and sedentary lifestyle Several medications promote long term weight gain Medications

25. What is the role of the brain in regulating appetite? 1. Badman MK & Flier JS. Science. 2005;307:1909–14; 2. van Bloemendaal L et al. Diabetes. 2014;63:4186–96; 3. Klok MD et al. Obes Rev. 2007;8:21–34; 4. Hall K et al. Am J Public Health. 2014;104:1169–75; 5. Berridge KC et al. Brain Res. 2010;1350:43–64; 6. Vallis M. Clin Obes. 2019;9:e12299; 7. Lau D et al. Canadian Adult Obesity Clinical Practice Guidelines: The Science of Obesity. Available from https://obesitycanada.ca/guidelines/science. Controlled by the brain’s reward system Eating for hunger Eating for pleasure Controlled by endocrine feedback signals Homeostatic eating Hedonic eating Executive function Self-regulatory processes influencing eating Deciding to eat Medication and surgery Medication and surgery Behavioral therapy Appetite is normally regulated by a complex interplay of different signals and areas in the brain. Increased understanding of the biology of appetite regulation has led to the development of new generation pharmacotherapy. The brain controls eating behavior and appetite. Weight is determined and regulated by a unique, three-layer appetite system.

26. Losing and maintaining weight loss with diet and exercise alone is a constant struggle. Nordmo M, et al. Obesity Rev 2020;21:e12949. Note: lifestyle interventions includes diet, exercise & behavioural therapy Despite best efforts, metabolic changes to weight loss promote weight regain I went on a diet and exercise programme last year and lost 30 kg, but despite continuing to exercise and eat well, I started regaining weight. I felt like a failure and it affected my mental health .

27. Introducing Wegovy®

28. Semaglutide is human GLP-1 analogue 94% homology to human GLP-1 t ½ of approximately 1 week HYP – – – PB BNST CEA AP NTS + Direct activation of the hindbrain (AP/NTS) Direct activation of the hypothalamus (HYP) Campos et al. Cell metabolism 2016;23(5):811-820; Friedrichsen et al. Diabetes Obes Metab 2021;23:754–62. Wegovy® is a GLP-1 RA that works in key areas of the brain to help control hunger and cravings CEA: CEntral nucleus of Amydala ; NTS: Nucleus Tractus Solitarius; AP: Area Postrema; HYP: Hypothalamus PB: ParaBrachial nucleus; BNST: bed nucleus of the stria terminalis

29. GLP-1: glucagon-like-peptide-1. GLP-1 RA: glucagon-like peptide-1 receptor agonist. Wegovy® is a GLP-1 RA that works in key areas of the brain to help control hunger and cravings Homeostatic regulation Wegovy® 2.4 mg increases satiety , making your patients feel less hungry 1 Hedonic regulation Wegovy® 2.4 mg reduces food cravings and preferences for certain foods 1

30. Wegovy® has been assessed in multiple phase III trials involving more than 26,000 participants *Semaglutide 2.4 mg is only indicated for weight management in appropriate patients and is not indicated for MASH. HFpEF : heart failure with preserved ejection fraction. MASH: metabolic dysfunction-associated steatohepatitis, formerly non-alcoholic steatohepatitis. MRCT: multi-regional clinical trial. WM: weight management 1. Wilding JPH, et al. N Engl J Med. 2021;384:989–1002 (STEP 1). 2. Davies M, et al. Lancet. 2021;397:971–84 (STEP 2). 3. Wadden TA, et al. JAMA. 2021;325:1403–13 (STEP 3). 4. Rubino D, et al. JAMA.2021; 325:1414–25 (STEP 4). 5. Garvey TW, et al. Nat Med. 2022;28:2083-91 (STEP 5). 6. Kadowaki T et al. Lancet Diabetes Endocrinol. 2022;10:193–206 (STEP 6). 7. Mu Y, et al. Lancet Diabetes Endocrinol. 2024;12:184–95 (STEP 7). 8. Rubino D, et al. JAMA. 2022;327:138–50 (STEP 8). 9. Bliddal H, et al. Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis. Oral presentation at OARSI 2024, Vienna, Austria (STEP 9). 10. ClinicalTrials.gov. (NCT05040971). https://clinicaltrials.gov/ct2/show/NCT05040971 (STEP 10). Accessed August 2024. 11. Weghuber D, et al. N Engl J Med. 2022;387:2245–57 (STEP TEENS). 12. Lingvay I, et al. Obesity (Silver Spring). 2023;31:111–22 (SELECT). 13. Kosiborod MN, et al. N Engl J Med. 2023;389:1069–84 (STEP HFpEF ). 14. Kosiborod MN, et al. N Engl J Med. 2024 DOI: 10.1056/NEJMoa2313917 (STEP HFpEF DM). 15. ClinicalTrials.gov. (NCT04822181). https://clinicaltrials.gov/study/NCT04822181 (ESSENCE). STEP 1 Weight management (WM) STEP 2 WM in type 2 diabetes STEP HFpEF DM Obesity and HFpEF with type 2 diabetes STEP HFpEF Obesity and HFpEF STEP 9 Obesity and osteoarthritis STEP 10 Obesity and pre-diabetes STEP 3 WM with intensive behavioural therapy STEP 4 Sustained WM STEP 5 Long-term WM STEP 6 East Asian STEP TEENS WM in adolescents STEP 7 China, Brazil, Korea & Hong Kong MRCT STEP 8 Obesity head-to-head vs liraglutide ESSENCE MASH outcomes* SELECT Obesity and cardiovascular outcomes STEP UP WM with 7.2 mg STEP UP T2D WM with 7.2 mg STEP 11 Korea, Thailand Over 33 million patient-years of exposure to Semaglutide

31. Semaglutide has been extensively studied in >3500 participants from INDIA GLP-1RA, glucagon-like peptide-1 receptor agonist; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity; STEP, semaglutide treatment effect in people with obesity. 1. Wilding JPH, et al. N Engl J Med. 2021;384:989–1002. 2. Davies M, et al. Lancet. 2021;397:971–84. 3. Wadden TA, et al. JAMA. 2021;325:1403–13. 4. Rubino D, et al. JAMA. 2021;325:1414–25. 5. Kosiborod MN, et al. N Engl J Med. 2023;21:1069–84. 6. Weghuber D, et al. N Engl J Med. 2022;387:2245–57. 7. Kadowaki T, et al. Lancet Diabetes Endocrinol. 2022;10:193–206. 8. Mu Y, et al. Lancet Diabetes Endocrinol. 2024;12:184–195. 9. Garvey WT, et al. Nat Med. 2022;28:2083–91. 10. Rubino DM, et al. JAMA. 2022;327:138–50. 11. Kosiborod MN, et al. N Engl J Med. 2024; DOI: 10.1056/NEJMoa2313917. 12. McGowan BM, et al. Lancet Diabetes Endocrinol. 2024;12:631-642 . 13. Lincoff AM, et al. N Engl J Med. 2023;DOI:10.1056/NEJMoa2307563. 14. ClinicalTrials.gov. NCT04998136 . 15. Bliddal H, et al. Obes Facts. 2024;17(suppl 1):72. 16. Bergmann NC, et al. Diabetes Obes Metab. 2023;25:18-35. 17. Data on file. Novo Nordisk A/S; Bagsværd, Denmark. SEMAGLUTIDE s.c. 2.4mg = Total 858 ORAL SEMAGLUTIDE = Total 1667 COMPLETED ONGOING 95 83 130 50 346 60 231 33 SEMAGLUTIDE s.c. 1.0mg = Total 1246 1 2 117 164 492 55 Total 828 218 25 Total 1028 Total 218 51 201 214 388 788 30 Total 30 Total 1642 Total 25

32. BMI: body mass index. BP : blood pressure. HbA 1c : glycated haemoglobin. 1. Wegovy® (semaglutide 2.4 mg) Approved Product Information. Available at www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/wegovypi.pdf. 2. Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). STEP 1: Wegovy® in patients with overweight/obesity 16 End of dose escalation 68 End of treatment 75 End of trial § Dose escalation O ff-treatment FU O ff-treatment FU 0.25 mg 0.5 mg 1.0 mg 1.7 mg 0.25 mg 0.5 mg 1.0 mg 1.7 mg Intensive behavioural therapy (IBT) Male or female ≥18 years BMI: ≥30 kg/m 2 or ≥27 kg/m 2 and ≥1 comorbidity Stable body weight ≥90 days HbA 1c < 6.5% Wegovy ® 2.4 mg s.c. OW # Placebo s.c. OW # Trial objectives To compare the effect of semaglutide 2.4 mg versus placebo # on body weight, cardiovascular risk factors, COAs, glucose metabolism, and other factors related to body weight To compare the safety and tolerability of semaglutide 2.4 mg versus placebo # Confirmatory secondary endpoints 10%- and 15%-responders Waist circumference, systolic blood pressure, SF-36 physical functioning, IWQOL-Lite-CT physical function Primary endpoints %-weight loss 5%-responders Lifestyle intervention Randomisation 2:1 N = 1961 1961 participants with overweight or obesity Week

33. STEP 1: Participants experienced significant weight loss with Wegovy® compared to lifestyle intervention alone # # Trial Product Estimand; *p<0.001 vs placebo. Mean baseline body weight and BMI was 105.3 kg and 37.9 kg/m 2 , respectively .1,2 94.9% of participants randomised to Sema 2.4 mg completed the STEP 1 study (n=1240/1306) and of these, 89.6% were receiving the 2.4 mg maintenance dose at Week 68. 1 Weight percentages shown are estimated from Week 0 to last contact with a trial site, regardless of treatment discontinuation or rescue intervention (treatment policy estimand). 1,2 BMI: body mass index. 1. Semaglutide 2.4 mg. Approved Product Information. Available at www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/wegovypi.pdf. 2. Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). 16.9% REDUCTION FROM WEEK 0 TO 68 with Wegovy ® 2.4 mg 2.4% REDUCTION FROM WEEK 0 TO 68 with Placebo Observed body weight change over time * (Mean at baseline: 105.3 kg)

34. 92.4% of patients achieved ≥5% weight loss when taken over 68 weeks as an adjunct to a reduced-energy diet and increased physical activity 1 # Trial Product Estimand *Not part of the statistical testing hierarchy; p-value not available (NA). Mean baseline body weight and BMI was 105.3 kg and 37.9 kg/m2, respectively.1,2 Weight proportions are estimated from Week 0 to last contact with a trial site, regardless of treatment discontinuation or rescue intervention (treatment policy estimand). 1,2 BMI: body mass index. Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). STEP 1 : Clinically meaningful weight loss with Wegovy® was achieved by the majority of patients # ≥20% weight loss in >1 in 3 patients Wegovy ® 2.4 mg Placebo

35. STEP 1: Several health parameters, including CV risk factors, were improved with Wegovy® plus lifestyle intervention All values are estimated as per the trial product estimand 1,2 CRP: C-reactive protein. CV: cardiovascular. NA: not available. SF-36: Short-Form 36-item Health Survey. 1. Wegovy® (semaglutide 2.4 mg) Approved Product Information. Available at www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/wegovypi.pdf. 2. Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). CONFIRMATORY SECONDARY ENDPOINTS SUPPORTIVE SECONDARY ENDPOINTS Waist circumference -15.2 cm with semaglutide 2.4 mg vs -4.5 cm placebo Systolic blood pressure -7.1 mmHg with semaglutide 2.4 mg vs -1.1 mmHg placebo SF-36 physical function score +2.56 with semaglutide 2.4 mg vs +0.5 placebo HbA 1c -0.5% with semaglutide 2.4 mg vs -0.16% placebo Diastolic blood pressure -3 mmHg with semaglutide 2.4 mg vs -0.6 mmHg placebo C-reactive protein -58.0% with semaglutide 2.4 mg vs -20.0% placebo

36. Study inclusion criteria ≥18 years of age BMI ≥30 kg/m 2 or BMI ≥27 kg/m 2 with at least one weight-related comorbidity No diabetes, HbA 1c <6.5% Baseline characteristics Female: 79% Mean age: 46 years Mean body weight: 107.2 kg Mean BMI: 38.4 kg/m 2 Mean waist circumference: 115.3 cm BMI: body mass index. BP : blood pressure. HbA 1c : glycated haemoglobin. Rubino D, et al. JAMA . 2021;325:1414–25 (plus supplementary appendix). STEP 4: Effect of maintaining Wegovy® vs treatment withdrawal Key endpoints at Week 68 Co-primary: Change in body weight from Week 20 Secondary: Change in waist circumference, systolic BP and physical functioning score from Week 20 75 End of trial Run-in period Randomised period Start of run-in 20 Randomisation (2:1) Baseline 68 End of treatment Wegovy ® dose escalation O ff-treatment follow-up O ff-treatment follow-up Wegovy ® 2.4 mg s.c. OW Placebo s.c. OW 2.4 mg 0.25 mg 0.5 mg 1.0 mg 1.7 mg Only participants who reached the maintenance dose of Wegovy ® were randomised 902 participants with overweight or obesity Week

37. STEP 4: The maintenance dose of Wegovy® helped patients sustain their weight loss over time # # Trial Product Estimand; *Mean change in body weight from Week 20 to Week 68 for those randomised to Wegovy® was -7.9%; p<0.001 vs placebo. Mean baseline body weight and BMI was 107.2 kg and 38.4 kg/m 2 , respectively .1,2 98.5% of participants randomised to Wegovy® at Week 20 completed the STEP 4 study (n=527/535) and of these, 89.5% were receiving the 2.4 mg maintenance dose at Week 68. 1 Weight percentages shown are estimated from Week 0 to last contact with a trial site, regardless of treatment discontinuation or rescue intervention (treatment policy estimand). 1,2 BMI: body mass index. Rubino D, et al. JAMA . 2021;325:1414–25 (plus supplementary appendix). ≥20% weight loss in >1 in 3 patients In-trial: Wegovy ® 2.4 mg Placebo Wegovy ®(run-in) Run-in period Body weight change (%) Time (week) 18.2% REDUCTION FROM WEEK 0 TO 68 with Wegovy ® 2.4 mg Participants in the placebo arm experienced weight regain despite continuing a reduced energy diet and increased physical activity

38. Study inclusion criteria ≥18 years of age BMI ≥30 kg/m 2 or BMI ≥27 kg/m 2 with at least one weight-related comorbidity No diabetes, HbA 1c <6.5% Baseline characteristics Female: 78% Mean age: 47 years Mean body weight: 106.0 kg Mean BMI: 38.5 kg/m 2 Mean waist circumference: 115.7 cm BMI: body mass index. HbA 1c : glycated haemoglobin. Garvey TW, et al. Nat Med. 2022;28:283–91 (plus supplementary appendix). STEP 5: Long-term maintenance of Wegovy® over 2 years Key endpoints at Week 104 Co-primary: Change in body weight ≥5% reduction in body weight Secondary: ≥10% and ≥15% reduction in body weight 304 participants with overweight or obesity Week 0 Randomization (1:1) Week 16 End of dose escalation Week 104 End of treatment Week 111 End of trial Dose escalation Wegovy ® 2.4 mg s.c. OW * Placebo s.c. OW * O ff-treatment follow-up O ff-treatment follow-up 0.25 mg 0.5 mg 1.0 mg 1.7 mg 0.25 mg 0.5 mg 1.0 mg 1.7 mg

39. STEP 5: Patients experienced sustained weight loss over 2 years with Wegovy® # Trial Product Estimand ; *p<0.001 vs placebo. Mean baseline body weight and BMI was 106.0 kg and 38.5 kg/m 2 , respectively .1,2 86.8% of participants randomised to Wegovy® completed the STEP 5 study (n=132/152) and of these, 90.9% were receiving the 2.4 mg maintenance dose at Week 104. 1 Weight percentages shown are estimated from Week 0 to last contact with a trial site, regardless of treatment discontinuation or rescue intervention (treatment policy estimand). 1,2 BMI: body mass index. Garvey TW, et al. Nat Med. 2022;28:283–91 (plus supplementary appendix). 16.7% REDUCTION FROM WEEK 0 TO 104 with Semaglutide 2.4 mg 0.6% REDUCTION FROM WEEK 0 TO 104 with Placebo Observed mean change over time (Mean at baseline: 106.0 kg) Body weight change (%) –4 –8 –12 –16 –20 Wegovy ® 2.4 mg Placebo ≥20% weight loss in >1 in 3 patients And the SELECT trial demonstrates that weight loss achieved with Wegovy ® is sustained over a period of four years when treatment is continued.

40. STEP 1, 4 and 5: The safety profile of Wegovy® is consistent with the GLP-1 RA class Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). 3. Rubino D, et al. JAMA . 2021;325:1414–25 (plus supplementary appendix). Garvey TW, et al. Nat Med. 2022;28:283–91 (plus supplementary appendix). Incidence vs placebo, % STEP 1 ( N=1,961; Week 0-68) STEP 4 ( N=803; Week 20-68) STEP 5 (N=304; Week 0-104) All adverse events 89.7 vs 86.4 81.3 vs 75.0 96.1 vs 89.5 Gastrointestinal adverse events 74.2 vs 47.9 41.9 vs 26.1 82.2 vs 53.9 Serious adverse events 9.8 vs 6.4 7.7 vs 5.6 7.9 vs 11.8 Fatal adverse events 0.1 vs 0.2 0.1 vs 0.2 0.7 vs 0 Adverse events leading to discontinuation 7.0 vs 3.1 2.4 vs 2.2 5.9 vs 4.6 Gastrointestinal adverse events leading to discontinuation 4.5 vs 0.8 Not reported 3.9 vs 0.7 Gastrointestinal side effects were generally mild-to-moderate and transient

41. Summary † 30.2% of patients in STEP 1 and 38.6% of patients in STEP 4 achieved ≥20% weight loss with Wegovy® 2.4 mg as an adjunct to a reduced-energy diet and increased physical activity; supportive secondary endpoint, p-value not available, not to be used to infer definitive treatment effect. 1–3 ^ 36.1% of patients in STEP 5 achieved ≥20% weight loss with Wegovy® 2.4 mg at Week 104; supportive secondary endpoint, p-value not available, not to be used to infer definitive treatment effect. 4 The most common side effects associated with Wegovy® were gastrointestinal (nausea=38%, diarrhoea=27%, constipation=22%, vomiting=22%, abdominal pain=18%), headache (13%) and fatigue (10%). 1 ‡ Significant improvements with Wegovy® 2.4 mg in waist circumference, systolic blood pressure and physical functioning as assessed by SF-36 score (confirmatory secondary endpoints; p<0.001 vs placebo). 1,2 Wegovy® 2.4 mg is only indicated for weight management in appropriate patients and is not indicated for the prevention of cardiovascular events. 1 Mean baseline body weight and BMI across STEP 1, 4 and 5 of 105–107 kg and 37.9–38.5 kg/m 2 , respectively. 1–4 BMI: body mass index. CV: cardiovascular. GLP-1 RA: glucagon-like peptide-1 receptor agonist. SF-36: 36-Item Short-Form Health questionnaire. 1. Wegovy® (semaglutide 2.4 mg) Approved Product Information. 2. Wilding JPH, et al. N Eng J Med. 2021;384:989–1002 (plus supplementary appendix). 3. Rubino D, et al. JAMA. 2021;325:1414–25 (plus supplementary appendix). 4. Garvey TW, et al. Nat Med. 2022;28:283–91 (plus supplementary appendix).; 5. Ryan DH, et al. Nat Med 2024. doi: 10.1038/s41591-024-02996-7 ≥20% weight loss in ~1 in 3 patients over 68 weeks; mean weight loss 15–17%, p<0.001 vs placebo 1–3† Sustained weight loss over 4 years with a safety profile consistent with the GLP-1 RA class 1–4^ Significant health gains in CV risk factors and physical function vs lifestyle intervention alone over 68 weeks 1,2‡ Wegovy® is suitable for adult patients from a BMI of ≥27 kg/m 2 in the presence of at least one weight-related comorbidity or ≥30 kg/m 2 regardless of any comorbidity 1